Skip to main content
Clinical Trials/NCT05546021
NCT05546021
Completed
Not Applicable

Influence of Nociception Level Monitor (NOL) During Guided Analgesic Delivery in Breast Surgeries on the Perioperative Course, Quality of Recovery and Hospital Stay

University of Southern Denmark1 site in 1 country60 target enrollmentSeptember 1, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Anesthesia; Adverse Effect
Sponsor
University of Southern Denmark
Enrollment
60
Locations
1
Primary Endpoint
Peroperative Morphine consumption
Status
Completed
Last Updated
9 months ago

Overview

Brief Summary

To assess if perioperative consumption of opioids can be optimized with the assistance of a Nociception Level (NOL) monitor in breast surgery patients receiving pectoral and parasternal nerve blocks as supplementation to general anaesthesia.

Hypothesis:

  1. NOL monitor guidance optimizes perioperative analgesic consumption and postoperative length of stay and offers a better quality of recovery in breast surgery.
  2. Intraoperative NOL monitoring can detect the efficacy of pectoralis and parasternal nerve blocks.
  3. Incidence of persistent neuropathic pain after breast cancer surgery is lower in patients receiving lower doses of perioperative opioids.

Detailed Description

Optimal perioperative pain management is important not only for patient satisfaction but also for hemodynamic stability and effective restitution. Despite being the principal element of anaesthesia, analgesia delivery has long been based on non-objective surrogate parameters such as blood pressure and heart rate. This may lead to hemodynamic inconsistency, poor restitution and patient dissatisfaction, which are some of the observed challenges. In that context, there has long been a search for a monitor which can guide the meticulous administration of analgesics. Recently, a nociception level monitor (NOL) based on an advanced software algorithm was developed using multiple physiological parameters. It offers an objective number (NOL Index) which relates to the level of intra-operative pain. NOL technology has been validated and found superior to existing pain indicators in peer-reviewed publications. With the availability of NOL monitors, a meticulous adjustment in the administration of opioids became a possibility. Therefore, the investigators are planning a randomised study to investigate if opioid consumption can be reduced and if immediate and long-term postoperative complications can be minimised.

Registry
clinicaltrials.gov
Start Date
September 1, 2023
End Date
February 28, 2024
Last Updated
9 months ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • American Society of Anaesthesiologists (ASA) class I-IV patients scheduled for an elective mastectomy with or without axillary resection

Exclusion Criteria

  • Inability to give consent,
  • atrial fibrillation,
  • local anesthetic allergy,
  • lumpectomy converted to Mastectomy.

Outcomes

Primary Outcomes

Peroperative Morphine consumption

Time Frame: during the surgery

(peroperative, mg)

Peroperative Remifentanil consumption

Time Frame: during the surgery

( peroperative, mg)

Secondary Outcomes

  • Length of time in recovery room(immediately after surgery)
  • Post-operative opioid consumption(immediately after the surgery)
  • Postoperative Maximum pain score(immediately after the surgery)
  • Requirement for additional antiemetic drugs(immediately after the surgery)
  • Eligible time to discharge(immediately after the surgery)
  • Length of hospital stay(From admission to discharge, up to 72 hours)
  • Incidence of post-operative nausea and vomiting(immediately after the surgery)
  • Persistent neuropathic pain after breast cancer surgery(up to 3 months after surgery)

Study Sites (1)

Loading locations...

Similar Trials